LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Inmode Ltd

Suletud

SektorTervishoid

14.31 0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.29

Max

14.45

Põhinäitajad

By Trading Economics

Sissetulek

-4.9M

22M

Müük

-2.4M

93M

P/E

Sektori keskmine

7.269

121.746

Aktsiakasum

0.38

Kasumimarginaal

23.467

Töötajad

599

EBITDA

-5.4M

26M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+23.57% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

27. apr 2026

Turustatistika

By TradingEconomics

Turukapital

98M

1B

Eelmine avamishind

14.1

Eelmine sulgemishind

14.31

Uudiste sentiment

By Acuity

50%

50%

127 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Inmode Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. veebr 2026, 23:21 UTC

Omandamised, ülevõtmised, äriostud

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. veebr 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. veebr 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. veebr 2026, 23:06 UTC

Tulu

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. veebr 2026, 23:04 UTC

Tulu

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. veebr 2026, 23:01 UTC

Tulu

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Shareholders to Receive A$5.20/Share in Cash

15. veebr 2026, 22:52 UTC

Omandamised, ülevõtmised, äriostud

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. veebr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. veebr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. veebr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. veebr 2026, 20:48 UTC

Tulu

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. veebr 2026, 20:47 UTC

Tulu

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. veebr 2026, 20:46 UTC

Tulu

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. veebr 2026, 20:45 UTC

Tulu

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. veebr 2026, 20:44 UTC

Tulu

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. veebr 2026, 20:43 UTC

Tulu

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. veebr 2026, 20:42 UTC

Tulu

BlueScope Net Debt A$2.2 Million at Dec. 31

15. veebr 2026, 20:42 UTC

Tulu

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. veebr 2026, 20:41 UTC

Tulu

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. veebr 2026, 20:40 UTC

Tulu

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. veebr 2026, 20:39 UTC

Tulu

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Võrdlus sarnastega

Hinnamuutus

Inmode Ltd Prognoos

Hinnasiht

By TipRanks

23.57% tõus

12 kuu keskmine prognoos

Keskmine 17.67 USD  23.57%

Kõrge 21 USD

Madal 15 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Inmode Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

14.1 / 14.44Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

127 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat